Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
Therapeutic Advances in Medical Oncology
|
August 11, 2021
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
Stephen P Hack, Wendy Verret, Sohail Mulla, et al.
Future Oncology (London, England)
|
May 1, 2020
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
Stephen P Hack, Jessica Spahn, Minshan Chen, et al.
Clinical Pharmacology and Therapeutics
|
May 22, 2023
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework
Colby S Shemesh, Phyllis Chan, Mathilde Marchand, et al.
Clinical Colorectal Cancer
|
July 2, 2013
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer
Johanna C Bendell, Thomas J Ervin, David Gallinson, et al.
Cancer Chemotherapy and Pharmacology
|
September 15, 2015
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors
Kelong Han, Jin Y Jin, Mathilde Marchand, et al.
Gynecologic Oncology
|
March 18, 2022
Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study
Amy P Hack, Ronald P Zweemer, Trudy N Jonges, et al.
JAMA Oncology
|
December 6, 2016
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial
Manish A Shah, Yung-Jue Bang, Florian Lordick, et al.
The Lancet. Oncology
|
June 6, 2020
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S Lee, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 20, 2019
Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients
E Roekevisch, K Szegedi, D P Hack, et al.
The British Journal of Dermatology
|
July 11, 2018
A minimally invasive tool to study immune response and skin barrier in children with atopic dermatitis
L Hulshof, D P Hack, Q C J Hasnoe, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
Therapeutic Advances in Medical Oncology
|
August 11, 2021
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
Stephen P Hack, Wendy Verret, Sohail Mulla, et al.
Future Oncology (London, England)
|
May 1, 2020
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation
Stephen P Hack, Jessica Spahn, Minshan Chen, et al.
Clinical Pharmacology and Therapeutics
|
May 22, 2023
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework
Colby S Shemesh, Phyllis Chan, Mathilde Marchand, et al.
Clinical Colorectal Cancer
|
July 2, 2013
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer
Johanna C Bendell, Thomas J Ervin, David Gallinson, et al.
Cancer Chemotherapy and Pharmacology
|
September 15, 2015
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors
Kelong Han, Jin Y Jin, Mathilde Marchand, et al.
Gynecologic Oncology
|
March 18, 2022
Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study
Amy P Hack, Ronald P Zweemer, Trudy N Jonges, et al.
JAMA Oncology
|
December 6, 2016
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial
Manish A Shah, Yung-Jue Bang, Florian Lordick, et al.
The Lancet. Oncology
|
June 6, 2020
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S Lee, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 20, 2019
Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients
E Roekevisch, K Szegedi, D P Hack, et al.
The British Journal of Dermatology
|
July 11, 2018
A minimally invasive tool to study immune response and skin barrier in children with atopic dermatitis
L Hulshof, D P Hack, Q C J Hasnoe, et al.
Page
of 4